Immunological synapses are initiated by signaling in discrete T cell antigen receptor microclusters and are important for the differentiation and effector functions of T cells. Synapse formation involves the orchestrated movement of microclusters toward the center of the contact area with the antigen-presenting cell. Microcluster movement is associated with centripetal actin flow, but the function of motor proteins is unknown. Here we show that myosin IIA was necessary for complete assembly and movement of T cell antigen receptor microclusters. In the absence of myosin IIA or its ATPase activity, T cell signaling was interrupted 'downstream' of the kinase Lck and the synapse was destabilized. Thus, T cell antigen receptor signaling and the subsequent formation of immunological synapses are active processes dependent on myosin IIA.
The specific and long-lasting interface between a T cell and an antigenpresenting cell (APC), called the 'immunological synapse' , is critical for the afferent and efferent limbs of the adaptive immune response 1, 2 . The supramolecular organization of the immunological synapse was described more than a decade ago [3] [4] [5] , yet the mechanisms leading to its formation and persistence are unknown. No function for motor proteins in signaling and synapse formation by cells of the immune system has been established 6, 7 .
The first step in synapse formation is engagement of the T cell antigen receptor (TCR) with the appropriate major histocompatibility complex-antigenic peptide complex, which leads to actin-dependent microcluster formation and recruitment of signaling components to form a signalosome within seconds [8] [9] [10] . The TCR signalosome includes tyrosine-phosphorylated forms of the kinase Lck (A001394), the kinase Zap70 (A002396) and the membrane adaptor Lat (A001392) and excludes the transmembrane phosphatase CD45 (refs. 8,9,11-13) . The contact area expands by integrin-mediated spreading as TCR microclusters continue to form at the outer edge 11, 13 . Over a period of minutes, the microclusters move to the center of the contact area, where they fuse into larger clusters and become part of the nonmotile central supramolecular activation cluster (cSMAC) 13 . As there is less tyrosine phosphorylation in the cSMAC, it has been suggested to be the site of inactivation of old clusters, whereas new microclusters form at the periphery 9, 13, 14 . The formation and movement of new TCR microcluster-based signalosomes toward the cSMAC sustains signaling 13 .
The driving force for protein rearrangement in the immunological synapse is unknown, although actomyosin-driven contraction has been proposed to drive TCR movement 15 . An alternative has been proposed on the basis of size-dependent segregation of proteins coupled with receptor-ligand interaction kinetics and membrane dynamics 16 . T cell synapses have been shown to have a centripetal version of retrograde actin flow 2, 17 , a process that propels growth cones of neurons and other motile cells 18 . A close examination of the centripetal movement of TCR microclusters shows that it is F-actin dependent and that they move at about half of the speed of the underlying actin cytoskeleton (140 nm/s versus 320 nm/s, respectively) and can change course to move around barriers 2, 17 . It has been proposed that intermittent coupling between the retrograde actin flow and the microclusters may drive centripetal movement, but the function of 'motors' in this process is not known.
Members of the nonmuscle myosin II subfamily are critical to many cellular functions, including cell polarization, migration, adhesion and cytokinesis 19 . Members of the myosin II family are composed of a heavy-chain dimer; each heavy chain is associated with two myosin light chains (MLCs). Nonmuscle myosin II is activated by phosphorylation of the MLCs to induce assembly into bipolar filaments and contraction after interaction with actin filaments 19, 20 . Three genes encode mammalian nonmuscle myosin II heavy chains, producing the following three isoforms: MyH9 (A004003), MyH10 and MyH14 (refs. 21, 22) . Of those three isoforms, only MyH9 is dominant in T cells 6, 23 . MyH9 pairs with regulatory MLCs to form a complex we refer to here by its common name, myosin IIA. T cell crawling and the movement of beads attached to the surface of T cells have been shown to require myosin IIA-mediated contractility 6, 24 . In both of those studies, the immunological synapse seemed to form in the absence of myosin IIA activity or in cells depleted of myosin IIA by small interfering RNA (siRNA). Myosin IIA was recruited to the synapse 6 , but its activation and function in signaling and synapse formation were not firmly established.
Here we show that the actin-based 'molecular motor' myosin IIA is an essential participant in the formation and persistence of immunological synapses and TCR signaling. Myosin IIA was rapidly activated after TCR engagement, and its activity was essential for the centripetal movement of TCR microclusters. Additionally, both immunological synapse stability and signaling 'downstream' of the TCR required intact myosin IIA.
RESULTS
TCR microcluster movement requires myosin IIA As translocation of TCR microclusters is an essential part of the formation of the immunological synapse, we first assessed whether myosin IIA was required for this motion. TCR microclusters can be tracked with a supported planar bilayer system and total internal reflection fluorescence (TIRF) microscopy 11, 13 . We used TIRF microscopy to image the motion of TCR microclusters in Jurkat T cells on supported planar bilayers containing laterally mobile Alexa Fluor 568-labeled antibody to TCR (anti-TCR; OKT3) and intercellular adhesion molecule 1 (ICAM-1) 17 . In agreement with published studies 17 , TCR microclusters in Jurkat T cells moved centripetally with an average velocity (± s.e.m.) of 0.15 ± 0.05 mm/s (P o 0.0001; Fig. 1a and Supplementary Movie 1 online) to generate the cSMAC. The average displacement of a microcluster from its point of formation to the cSMAC was 2.6 ± 0.8 mm (P o 0.0001), and the meandering index, calculated as displacement divided by track length, was 0.83 ± 0.09 (P o 0.0001); both are consistent with published values 17 . To assess the involvement of myosin IIA activity in microcluster translocation, we first treated the Jurkat T cells with blebbistatin, a well established specific inhibitor of myosin II ATPase activity 25 . Jurkat T cells pretreated for 10 min with blebbistatin (50 mM) formed microclusters but showed less directed microcluster movement, with an average speed of 0.06 ± 0.02 mm/s, a displacement of 0.25 ± 0.13 mm and a meandering index of 0.17 ± 0.09 (P o 0.0001 for all measurements; Fig. 1a and Supplementary Fig. 1 and Supplementary Movie 2 online). We detected equivalent blockade of microcluster centripetal motion with ML-7 an inhibitor of myosin light-chain kinase (MLCK; Supplementary Movie 3 online). We noted similar effects on the inhibition of microcluster movement when we inhibited myosin IIA activity in primary human CD4 + T cells by treatment with blebbistatin (Supplementary Movies 4-6 online).
Thus, the microclusters continued to move at 40% the speed of control Jurkat T cells but with over fourfold more meandering and only 10% of the displacement of control Jurkat T cells (treated with DMSO). In mature synapses with formed cSMACs, blebbistatin treatment did not disrupt the cSMAC, but the peripheral TCR microclusters ceased directed movement shortly after addition of the drug (Supplementary Movie 7 online). These results suggest that myosin IIA activity is required for the centripetal movement of TCR microclusters but not for microcluster formation.
To further assess the involvement of myosin IIA in the translocation of TCR microclusters, we targeted MyH9 by siRNA. Jurkat T cells did not recover sufficiently from nucleofection of control siRNA to form mature synapses (data not shown). As myosin II is required for cytokinesis 19 , siRNA vectors that require growth and selection would also not be usable. Therefore, we 'knocked down' MyH9 in primary activated human CD4 + T cells, which recover well from nucleofection. The best knockdown efficiency achieved in the primary T cells was 35%, as assessed by immunoblot analysis (data not shown). However, immunofluorescence analysis showed that this was due to nearly complete knockdown of MyH9 in one third of cells (data not shown). We analyzed microcluster tracking on planar bilayers of all cells in several microscopic fields while indexing the x-y coordinates of the fields, then fixed the cells and stained for intracellular MyH9, which allowed us to identify the cells in which MyH9 was 'knocked down' in the previously tracked and indexed cells. Primary T cells depleted of MyH9 failed to form the typical condensed cSMAC and instead had small, scattered TCR microclusters (Fig. 1b) . TCR microclusters in cells treated with control siRNA had an average centripetal velocity of 0.12 ± 0.034 mm/s, with an average displacement of 2.2 ± 0.53 mm and a meandering index of 0.85 ± 0.07 (P o 0.0001 for all measurements). TCR microclusters in MyH9-deficient cells had a speed of 0.062 ± 22 mm/s, a displacement of 0.26 ± 0.11 mm and a meandering index of 0.25 ± 0.11 (P o 0.0001 for all measurements; Supplementary Fig. 1 ). Notably, there was significantly less TCR accumulation at the cSMAC (P o 0.0001) but only slightly, nonsignificantly less total TCR in the entire contact area in cells depleted of MyH9 (Fig. 1c) . These results obtained by siRNA knockdown of MyH9 expression reproduced the results obtained by inhibition of myosin II activity with blebbistatin and ML7. Thus, myosin IIA activity is required for the translocation of TCR microclusters to form a cSMAC but not for the formation of TCR microclusters. Myosin IIA is activated during T cell stimulation Our initial results indicated that myosin IIA participates in the formation of the immunological synapse. Activation of myosin IIA through phosphorylation of MLCs during the formation of the immunological synapse has not been evaluated so far. We therefore examined the phosphorylation status of MLCs in Jurkat T cells stimulated either with soluble OKT3, which activates the TCR only, or with 'superantigen' presented by Raji B cells as APCs, which engages the TCR and multiple adhesion and costimulatory molecules. MLCs were not detectably phosphorylated in resting Jurkat T cells, but within 30 s of stimulation by soluble OKT3, they became phosphorylated and this phosphorylation was sustained for at least 30 min (Fig. 2a) . In resting Jurkat T cells, myosin IIA was uniformly distributed in the cytoplasm, whereas after stimulation with soluble OKT3, myosin IIA and its phosphorylated MLCs rapidly became enriched at the area of TCR clusters at the plasma membrane (Fig. 2b,c) .
In synapses formed between Jurkat T cells and 'superantigen'-loaded Raji B cells, we detected the typical accumulation of TCR, F-actin and ezrin at the contact site as described before 26, 27 . In a twocell system, either the T cell or B cell could contribute to this protein redistribution, yet the results obtained with immune synapses between Jurkat and Raji B cells were identical to results obtained with Jurkat T cells stimulated with soluble OKT3 and were indicative of a seemingly normal immune synapse (Figs. 2 and 3). The synapse was also highly enriched for myosin IIA, with a distribution very similar to that of the TCR (Fig. 3a) . We obtained similar results with primary human CD4 + T cells ( Supplementary Fig. 2 online) . The recruitment of activated myosin IIA to the immunological synapse is consistent with the observed function of myosin IIA in the movement of TCR microclusters and cSMAC formation.
Immunological synapse stability requires myosin IIA To understand the consequences of myosin IIA activity for the immunological synapse, we determined the effect of pretreating Jurkat T cell with 50 mM blebbistatin on synapse formation with 'superantigen'-loaded Raji B cells. Unexpectedly, we found that inhibition of myosin II activity did not inhibit the concentration of TCR, ezrin, F-actin or myosin IIA itself at the contact site between the two cells (Fig. 3b) . As we could not use siRNA in the Jurkat model, we used both ML7 and an additional inhibitor, Y27632, which inhibits Rho-associated kinase (ROCK). Both ROCK and MLCK phosphorylated and activated MLCs, and both ML7 and Y27632 inhibited phosphorylation of MLCs during T cell stimulation with soluble anti-TCR ( Supplementary Fig. 3 online) . Conjugates between 'superantigen'-loaded Raji B cells and Jurkat T cells pretreated with either of those drugs had apparently normal accumulation of myosin IIA ( Supplementary Fig. 4 online). We obtained similar results with primary human CD4 + cells pretreated with blebbistatin and incubated for 5 min with Raji B cells ( Supplementary Fig. 2 ). These data confirm and extend earlier indications that the first attachment step of immunological synapse formation does not require myosin IIA activity 6 . These results were also consistent with the ability of blebbistatin-treated or myosin IIA-depleted cells to form immature immunological synapses on planar bilayers containing TCR microclusters and ICAM-1 ( Fig. 1) .
Although the conjugates formed after inhibition of myosin IIA seemed normal, we found that fewer total conjugates formed with T cells pretreated with 50 mM blebbistatin than with control cells treated with DMSO (Fig. 3c) . Conjugate formation was not further decreased by pretreatment with 100 mM blebbistatin (data not shown), which suggested that the residual conjugate formation was not simply an effect of partial inhibition of myosin IIA activity. To explore the basis for the lower conjugate number, we examined the effect of blebbistatin addition before and after conjugate formation. We first immobilized 'superantigen'-loaded Raji B cells in dishes with coverslip inserts and then added Jurkat T cells. We monitored conjugate formation and stability by differential interference contrast (DIC) microscopy, adding blebbistatin at various times relative to conjugate formation (Fig. 4a) . The addition of blebbistatin resulted in lower stability of formed conjugates so that only about 20% remained 2 min after drug addition (Fig. 4b) . Jurkat T cells treated with blebbistatin formed unstable synapses that only lasted for 102 ± 14 s (Fig. 4c) , whereas control T cells formed stable synapses that persisted for over 20 min (data not shown). The addition of blebbistatin at various times after conjugate formation resulted in instability and detachment within 1-2 min of drug addition, with an average time of 109 s (Fig. 4c) .
As blebbistatin resulted in the same instability regardless of the time of addition after synapse formation, we concluded that myosin IIA activity is needed to maintain the stability of both early and mature synapses. We obtained similar results by inhibiting myosin IIA activation with 10 mM ML7 (Supplementary Movie 8 online) and with primary human CD4 + cells (Supplementary Movies 9,10 online).
We next assessed whether synapse breakdown resulted from perturbation of the typical accumulation of the adhesion proteins LFA-1 and ICAM-1 at the peripheral SMAC 5 after inhibition of myosin IIA activity with blebbistatin. Pretreatment with blebbistatin led to a more peripheral distribution of these interactions, consistent with impaired transport toward the center. However, we did not detect a difference in the intensity of these interactions relative to that of control cells treated with DMSO ( Supplementary Fig. 5 online) . Thus, instability of the immunological synapse after the inhibition of myosin IIA activity was not due to initial failure of LFA-1 activation.
Ca 2+ signaling requires myosin IIA activity One of the earliest and most easily monitored signaling events after T cell activation is a rapid increase in cytoplasmic Ca 2+ 
(ref. 28).
A published study has shown that treatment with butanedione monoxide, a less specific inhibitor of myosin II than blebbistatin, in activated primary CD4 + T cells leads to a less sustained increase in Ca 2+ after stimulation and a partial blockade of the movement of membrane proteins to the synapse 24 . To explore if synapse instability correlated with loss of Ca 2+ signaling, we preloaded Jurkat T cells with the fluorescent, cytoplasmic, Ca 2+ -sensitive indicator dye Fluo-LoJo and assessed the effect of blebbistatin on cytoplasmic Ca 2+ in response to 'superantigen'-loaded Raji B cells. Although control Jurkat T cells maintained higher cytoplasmic Ca 2+ concentrations (Fig. 5a,b) , the addition of blebbistatin (50 mM) to an existing immunological synapse led to a rapid decrease in Ca 2+ concentrations within 1 min (Fig. 5a, and Supplementary Fig. 6b online) . We obtained similar results with ML-7 (Supplementary Movie 11 and Supplementary Fig. 7 online).
We detected a similar decrease in Ca 2+ concentrations in primary human CD4 + cells after inhibition of myosin IIA (Supplementary Movies 12-14 online). For a more quantitative measurement of cytoplasmic Ca 2+ changes, we loaded Jurkat T cells with the ratiometric Ca 2+ -indicator dye Fura-2AM and calculated emission ratios. The addition of 50 mM blebbistatin to cells with preformed synapses diminished cytoplasmic Ca 2+ concentrations to baseline within less than 2 min, whereas control cells maintained high Ca 2+ concentrations (Fig. 5c) . Pretreatment with 50 mM blebbistatin blocked the TCR-induced increase in Ca 2+ altogether (Fig. 5c) . To rule out the possibility that emission-intensity changes resulted from autofluorescence of blebbistatin, we preloaded T cells with Fluo-LoJo and added blebbistatin without any TCR stimulation. Blebbistatin fluorescence was negligible in our assays ( Supplementary Fig. 6 ). Moreover, we found that the addition of 50 mM blebbistatin to the cells, followed by illumination, had no toxic effect (data not shown). Notably, in all these experiments, the decrease in cytoplasmic Ca 2+ concentration preceded the detachment of the immunological synapse, which indicated that myosin IIA activity is necessary for sustained Ca 2+ signaling 'downstream' of the TCR in the immunological synapse independently of any effects on adhesion.
The serial-triggering model holds that one major histocompatibility complex-bound antigenic peptide engages a large number of TCRs in successive rounds, contacting about 50-200 receptors per antigenic peptide 29 . This model is compatible with the demonstration that ten complexes of peptide and major histocompatibility complex in the T cell-APC interface can sustain signaling long enough to generate interleukin 2 (ref. 30) . If myosin IIA is needed only to promote an active process of serial triggering, then increasing the number of TCRs triggered in parallel might overcome the requirement for myosin IIA activity. To test that possibility, we explored whether more activating anti-TCR could overcome the effect of blebbistatin on Ca 2+ signaling. We preloaded Jurkat T cells with Fluo-LoJo and then stimulated the cells with increasing concentrations of anti-TCR. Once the cytoplasmic Ca 2+ concentrations had risen, we added 50 mM blebbistatin and monitored Ca 2+ concentrations for an additional 1 min. The decrease in cytoplasmic Ca 2+ concentration was independent of the concentration of activating antibody, with a similar decrease in cells stimulated with between 10 mg/ml and 500 mg/ml of antibody ( Supplementary  Fig. 8 online) . This result challenges the possibility of insufficient TCR engagement as a mechanism to account for the decrease in Ca 2+ signaling.
TCR signaling requires myosin IIA activity Our results suggested that myosin IIA might be important for the function of the TCR signalosome. The simplest way to activate the formation of TCR signalosomes is based on the addition of soluble anti-CD3e to Jurkat T cells 31 , shown above to activate MLC phosphorylation. We incubated Jurkat T cells with fluorescence-tagged anti-CD3e and monitored TCR distribution and biochemical indicators of TCR signalosome assembly (phosphorylation of Lck, Zap70 and Lat). Control Jurkat T cells initially showed a uniform surface fluorescence that aggregated into microclusters with a diameter of 280 ± 70 nm by 1 min, followed by coalescence into larger clusters of 456 ± 88 nm after 5 min of stimulation (Fig. 6a,b) . When we pretreated Jurkat T cells for 5 min with 50 mM blebbistatin and then stimulated the cells for 1 min with labeled anti-TCR, the TCR clusters were slightly smaller, with a diameter of 217 ± 63 nm. However, progression in cluster size in the blebbistatin-treated cells was minimal, reaching a diameter of 247 ± 66 nm after 5 min of stimulation (Fig. 6a,b) . We next explored the effect on microclusters when we added blebbistatin at 1 or 5 min after stimulation. In both cases, 5 min after the addition of blebbistatin, the cluster was smaller, with a diameter of 217 ± 64 nm or 258 ± 59 nm for 1 min or 5 min, respectively (Fig. 6a,b) . These results collectively show that TCR microclusters about 217 nm in diameter can form in the absence of myosin IIA activity, yet their coalescence into larger clusters and their maintenance in larger clusters require myosin IIA activity. We obtained similar results with primary human CD4 + cells (Supplementary Fig. 2) . When we treated Jurkat T cells for 2 min with antiCD3e and then analyzed phosphorylated signalosome components by direct immunoblot of lysates, we found that phosphorylation of Src kinases, which probably included phosphorylated Lck, was similar with or without blebbistatin pretreatment (Fig. 6c) . In contrast, phosphorylation of Zap70 and Lat was substantially lower after blebbistatin pretreatment (Fig. 6c) . We obtained similar results with primary CD4 + T cells (Supplementary Fig. 2 ). We also assessed whether Jurkat T cells pretreated with blebbistatin increased their Ca 2+ in response to stimulation with soluble anti-CD3e. T cells preloaded with Fluo-LoJo and stimulated with soluble anti-TCR underwent a robust Ca 2+ response, whereas cells pretreated with blebbistatin failed to increase Ca 2+ concentrations in response to stimulation (Fig. 5c and Supplementary Fig. 8) . These results indicate quantitative defects in TCR microcluster size and defective signalosome function in a synapse-free assay. TCR signalosome function can also be evaluated in a synapse-based system with supported planar bilayers presenting OKT3 (ref. 17) . T cells interacting with a planar bilayer containing OKT3 and ICAM-1 for 5 min had a central condensed TCR cluster surrounded by peripheral microclusters containing TCRs, as well as phosphorylated Zap70 and Lat (Fig. 7) , similar to published studies 9 . When we added Jurkat T cells pretreated with 50 mM blebbistatin to the bilayers, followed by staining with a specific antibody to each phosphorylated protein, we found that phosphorylated Src was localized together with TCR microclusters, but the abundance of phosphorylated Zap70 and Lat, as measured by fluorescence intensity, was significantly lower, by 80% each (P o 0.0001; Fig. 7) . We also extended this analysis to primary CD4 + T cells treated with control and MyH9-specific siRNA during activation; this resulted in nearly complete knockdown of myosin IIA in one third of the cells. We found that knockdown of myosin IIA diminished phosphorylation of Src by only 25% (P o 0.0001) but lowered phosphorylation of Zap70 at tyrosine 319 by 80% (P o 0.0001) and phosphorylation of Lat by 70% (P o 0.0001). These data demonstrate, by both pharmacological and reverse-genetic approaches, that myosin IIA is required for amplification of TCR signaling between the Lck and Zap70 activation steps.
DISCUSSION
Here we have provided evidence that myosin IIA is central to synapse assembly and signaling, being necessary for TCR signaling, the centripetal motion and fusion of microclusters during the formation of the immunological synapse, and synapse persistence. Published work has shown that the F-actin cytoskeleton is required for all of these processes 17, 32 and that TCR engagement induces actin polymerization through recruitment of the adaptor protein Nck and WiskottAldrich syndrome protein to the TCR microclusters 33 . Our study has shown that after T cell engagement, myosin IIA was activated by phosphorylation of MLCs and its activity was necessary for proper assembly of the signalosome. Inhibition of myosin IIA activity with the highly specific myosin II inhibitor blebbistatin or depletion of myosin IIA expression with specific siRNA resulted in a complete halting of directed motion of microclusters, prevented the formation of the cSMAC and prevented amplification of TCR signals after Lck activation. Whether myosin IIA activity was inhibited pharmacologically, in which case myosin IIA was still recruited to the synapse, or if its expression was diminished by siRNA, in which case it was profoundly depleted from the synapse, the formation of initial small TCR microclusters remained intact. However, these clusters did not increase in size, did not fully signal and did not undergo directed translocation. Thus, we have defined distinct F-actin-dependent and actomyosin-dependent phases of T cell activation and immunological synapse formation.
The potential involvement of myosin II in the formation of immunological synapses has been reported before. One study showed that movement of ICAM-1-coated beads on T cells after activation by a B cell is inhibited by butanedione monoxime with concurrent decrease in Ca 2+ signaling, although the B cell-T cell conjugates remain stable 24 . The authors hypothesized that myosin II-mediated transport is delivering components to the immunological synapse that are needed for sustained signaling. Another study showed that myosin IIA is necessary for T cell motility and uropod maintenance and postulated that inhibition of myosin IIA filament formation is required for the T cell 'stop signal' after antigen encounter 6 . These authors also reported that immunological synapse formation seemed unaffected by pretreatment with blebbistatin. That result is in agreement with our finding that immunological synapses formed with blebbistatin-treated T cells were initially similar to synapses with control cells. The T cell blasts used in the earlier study 6 have high constitutive LFA-1 activity, so myosin IIA-dependent signaling is not required for conjugate formation. We focused on two systems here, Jurkat T cells and primary human T cells, in which basal LFA-1 activity is low and 'inside-out' signaling through the TCR is required for conjugate formation 34 . In retrospect, evidence of spreading and contraction in the immunological synapse formation process was visible in earlier studies 5,9 and has been explicitly described for B cell synapse formation without indicating involvement of myosin II (ref. 35) . Contractile oscillations have been reported at the outer edge of the immunological synapse formed by T cells 32 . Contractile oscillations require myosin IIA in fibroblasts. Our results suggest that this is also probably true in lymphocytes 36 .
Myosin II-based cortical movement has been documented in several other situations. Myosin II is necessary for cortical tension and functions in the contractile ring during cytokinesis 37, 38 . Several studies have suggested that an imbalance in cortical tension contributes to cytokinesis, with cortical loosening at the cell poles and enhanced tension at the cell equator, leading to equatorial movement, assembly and contraction of the contractile ring 39 . In a related mechanism, anterior-posterior polarity in the one-cell nematode embryo is established by myosin II-mediated cortical contraction, which moves granules and fate determinants toward the future anterior pole 40 . It is possible that a related myosin II-dependent cortical tension may move TCR microclusters toward the center of the immunological synapse. Such cortical tension seemed to be required for TCR signalosome function even in the absence of a synapse, on the basis of results obtained with soluble OKT3. The reported particle-size requirements for T cell stimulation may arise from the need for myosin IIA-mediated tension across an interface or crosslinked protein network 41, 42 . Myosin IIA-mediated cortical tension may be required for the rearrangement of cytoskeletally associated 'protein islands' into functional signalosomes 43 .
The activation of myosin II by phosphorylation of its MLCs can be mediated by several different kinases, including the calciumcalmodulin-dependent MLCK 44 , ROCK and protein kinase C 45 . Shortly after stimulation of T cells, Vav1, a Rho guanine-exchange factor, is recruited to TCR microclusters through interaction with the adaptor protein SLP-76, which is then followed by the recruitment of the GTP-binding protein Cdc42 and ROCK 46, 47 . T cell stimulation also results in more cytoplasmic Ca 2+ , which is known to activate MLCK 44 . We have shown that treatment with either the ROCK inhibitor Y27632 or the MLCK inhibitor ML-7 inhibited phosphorylation of MLCs after T cell stimulation. Thus, both kinases take part in activating myosin II even when the TCR is triggered by OKT3. As myosin IIA activity was necessary to maintain higher Ca 2+ concentrations, a plausible model is that Rho-GTP-activated ROCK initially phosphorylates MLCs, then Ca 2+ concentrations increase, which maintains light-chain phosphorylation through persistent activation of MLCK. Thus, one crucial function of myosin IIA activity is to maintain signaling that then feeds back to maintain higher Ca 2+ concentrations and active myosin IIA. This is the first report to our knowledge to link myosin II activity to signaling through an immunoreceptor. In examining the 'downstream' signaling pathway, we found that phosphorylation of the Src family kinases was unimpaired by either inhibition or depletion of myosin IIA, whereas 'downstream' signaling, including phosphorylation of Zap70 and Lat and an increase in cytosolic Ca 2+ , were much more dependent on myosin IIA activity. The truncation in signaling 'downstream' of Lck was not due to defects in adhesion, as inhibition of myosin IIA activity in Jurkat T cells stimulated with soluble OKT3 also resulted in less phosphorylation of Zap70 and Lat and a decrease in intracellular Ca 2+ concentrations to baseline. Our data support a twostep model in which initial conjugate formation involving the formation of TCR microclusters, recruitment of myosin IIA and activation of Lck are all independent of myosin IIA activity, whereas amplification of signaling and microcluster movement are dependent on myosin IIA activity. Our work here and published work indicates that there is careful 'tuning' of myosin IIA activity during T cell activation, with negative regulation through inhibition of the formation of thick filaments 6 and positive regulation through phosphorylation of MLCs, which leads to maintenance of the cortical tension needed for TCR signaling and synapse stabilization.
METHODS
Cells and antibodies. Jurkat T cells and Raji B cells were from American Type Culture Collection. Human peripheral blood lymphocytes were isolated from citrate-anticoagulated whole blood by dextran sedimentation (Blood Centers of America-hemerica), followed by density separation over Ficoll-Hypaque (Sigma). The resulting mononuclear cells were washed in PBS and were further purified by nylon wool and plastic adherence as described 48 . Human peripheral CD4 + blasts were prepared as described 49 . Anti-ezrin and anti-myosin II heavy chain have been described 50 . Affinity-purified polyclonal antibodies to MLC phosphorylated at serine 19 (3671), Src phosphorylated at tyrosine 416 (used to measure phosphorylated Lck, the most abundant Src member in T cells; 2101), Zap 70 phosphorylated at tyrosine 319 (2701), and Lat phosphorylated at tyrosine 191 (3584) were from Cell Signaling. OKT3 mouse anti-human CD3 was purified from an OKT3 hybridoma cell line (14-0037; eBioscience). Rhodaminephalloidin, Alexa Fluor 568-phalloidin, Alexa Fluor 488-conjugated donkey anti-mouse (21202) and Alexa Fluor 568-conjugated goat anti-rabbit (11011) and goat anti-mouse (11004) were from Invitrogen. Horseradish peroxidaseconjugated goat anti-rabbit (W4011) was from Promega. All procedures were approved by the Health and Safety Committee of Cornell University.
Immunofluorescence. Cells were plated on poly-L-lysine-coated glass slides, were fixed for 30 min at 25 1C with 3.7% (wt/vol) formaldehyde, were made permeable by treatment for 2 min with 0.1% (vol/vol) Triton X-100 in PBS and then were rinsed three times in PBS. Cells were then incubated for 1 h with 5% (vol/vol) BSA in PBS, then were incubated for 1 h with primary antibody in 5% (vol/vol) BSA in PBS, washed in PBS and incubated for 1 h with the appropriate secondary antibody (or phalloidin) in 5% (vol/vol) BSA in PBS. After additional washes, 5 ml Vectashield (Vector Labs) was added to cells and slides were covered with coverslips. Cells were viewed with a Nikon Eclipse TE2000-U (100Â objective; numerical aperture, 1.4) with the Perkin Elmer UltraVIEW LCI spinning-disk confocal imaging system and a Hamamatsu 12-bit C4742-95 digital charge-coupled device camera.
Immunoblot analysis. Jurkat and primary T cells were lysed and were resolved by SDS-PAGE, followed by transfer to polyvinylidene difluoride membranes (Immobilon-P; Millipore) with a semidry transfer system (Integrated Separation Systems). After 1 h of blocking in 5% (wt/vol) milk in Tris-buffered saline with Tween, membranes were incubated for 1 h with primary antibody, then were washed and were incubated for 1 h with the appropriate horseradish peroxidase-conjugated secondary antibody. Blots were developed by the enhanced chemiluminescence system (Amersham).
Cell stimulation and conjugate formation. Jurkat and primary human T cells were activated for various times with the antibody OKT3 (10 mg/ml). For stimulation with B cells, Raji B cells were labeled with the fluorescent dye CellTracker Red (CMTPX; Molecular Probes) and were loaded with the 'superantigen' staphylococcus enterotoxin E (SEE; 2 mg/ml; Toxin Technology). Equal numbers of T cells and B cells were incubated together.
Conjugate stability and DIC microscopy. Raji B cells were loaded with SEE superantigen and then were immobilized in dishes containing coverslip inserts (MatTek) and viewed on an Axiovert 100 TV microscope (Carl Zeiss) equipped with a charge-coupled device (C4742-95-12ERG; Hamamatsu) with a DIC prism and Openlab 4.0 software (Improvision). After initial B cell imaging, Jurkat T cells or primary human T cells were added to plates and cells were allowed to form conjugates. Blebbistatin (50 mM), ML7 (10 mM) or DMSO was added at various times and conjugates were continuously imaged. Movies were analyzed with ImageJ software.
Ca 2+ assays. For nonratiometric assays, Jurkat T cells and primary human T cells were loaded with 1 mM Fluo-LoJo (TefLabs), then were added to SEE-loaded Raji B cells and allowed to form synapses or were stimulated with OKT3. Blebbistatin, ML7 or DMSO was added at various times and fluorescence intensity was measured with the spinning-disk confocal imaging system. For ratiometric analysis, Jurkat T cells were loaded with 2.5 mM Fura-2AM (acetoxymethyl ester; Molecular Probes) as described 13 .
Bilayer assembly and TIRF microscopy. Glass-supported bilayers of dioleoyl phosphatidylcholine incorporating 0.01% (wt/vol) 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(cap biotinyl) were prepared in flow chambers (Bioptechs) as described 5 . Bilayers were loaded with monobiotinylated-564-OKT3. Cells were allowed to settle and form contacts with the bilayer before imaging. An Olympus inverted IX-70 microscope equipped with Hamamatsu 12-bit C9100 1.1B charge-coupled device and a TIRF objective from Olympus were used for all bilayer imaging. Microclusters were analyzed with Volocity 4.2 (Improvision).
Transfection with siRNA. CD4 + human T cell blasts (3 Â 10 6 ) at day 4 after isolation were transfected by electroporation with Amaxa nucleofector technology according to the manufacturer's instructions. Two siRNA duplexes specific for human MYH9 and negative control siRNA were used (Dharmacon). Cells were cultured for 48 h and were analyzed by immunoblot or immunofluorescence. Suppression of the target protein was verified by immunoblot.
Statistical analysis. Prism software was used for nonparametric t-tests.
Accession codes UCSD-Nature Signaling Gateway (http://www.signalinggateway.org): A001394, A002396, A001392 and A004003.
Note: Supplementary information is available on the Nature Immunology website.
